Skip to main content

Table 3 Changes in FEV1 and in methacholine and AMP responsiveness in the SIT and placebo groups.

From: Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study

 

Baseline

6 months

12 months

SIT group

   

   FEV1, L

3.31 (2.99-3.63)

3.32 (3.01-3.64)

3.31

   Methacholine BRI, %/log mg/dl

7.2 (4.3-10.1)

7.2 (4.8-9.5)

7.4 (5.2-9.5)

   AMP BRI, %/log mg/dl

3.6 (2.3-5.0)

4.5 (2.9-6.1)

4.1 (2.7-5.4)

Placebo group

   

   FEV1, L

3.69 (3.21-4.17)

3.59 (3.15-4.03)

3.64 (3.20-4.07)

   Methacholine BRI, %/log mg/dl

7.1 (4.7-9.7)

7.2 (4.7-9.7)

6.6 (4.4-8.9)

   AMP BRI, %/log mg/dl

3.7 (2.1-5.3)

3.8 (1.8-5.7)

4.8 (3.0-6.6)

  1. Values are expressed as mean (95% confidence interval). For abbreviations see Table 2.
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us